Skip to main content
. 2019 Jan 11;10(4):480–493. doi: 10.18632/oncotarget.26558

Figure 5. Synergistic effect of AZD4547 and cisplatin on LGACC cell viability.

Figure 5

(A) Dose-dependent viability curves showing the half-maximal effective dose (EC50) for cisplatin and AZD4547. (B) Isobologram of synergistic cooperation between cisplatin and AZD4547 on LGACC cell viability (points plotted) over a 72 hrs. period. (C) Western blot analysis of LGACC cells following treatment with cisplatin, AZD4547, and their combination. (D) The quantitative expression of indicated proteins as determined by densitometric analysis. Data are calculated from triplicate experiments and presented as mean±SD (**p<0.05; ***p<0.01 compared with control; #p<0.05 wrt to cisplatin; +p<0.05 wrt to AZD4547).